Tumor vaccine
US10279020B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jul 29, 2015 |
| Grant date | May 7, 2019 |
| Priority date | — |
| Expiry date | Jan 10, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/86
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the fields of medicine, immunology, and oncology. More specifically, the invention relates to methods and compositions for inducing an immune response against a tumor in an animal subject. The invention provides that a lung cancer cell or other tumor cells, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen, and method for stimulating an immune response to a tumor with the tumor cell so genetically modified. The invention additionally provides a method of inhibiting a tumor, including a cancer such as lung cancer, by administering an allogeneic tumor cell, for example a cancer tumor cell such as a lung cancer tumor cell, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.